A Study of LY3002813 in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ)

NCT03367403 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

272

Enrollment

INDUSTRY

Sponsor class

Conditions

Alzheimer Disease

Interventions

DRUG: Donanemab
DRUG: Placebo
DRUG: LY3202626

Sponsor

Eli Lilly and Company